Emer Conroy

Emer Conroy

Auto-generated profile, based on publicly available information

Emer Conroy

UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin 4, Ireland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2016 in Nature Communications
Verified
Journal Article
Open access
MGMarco Grossi
Marco Grossi
MMMarina Morgunova
Marina Morgunova
SCShane Cheung
Shane Cheung
DSDimitri Scholz
Dimitri Scholz
ECEmer Conroy
Emer Conroy
DODonal O'Shea
Donal O'Shea
Bioresponsive NIR-fluorophores offer the possibility for continual visualization of dynamic cellular processes with added potential for direct translation to in vivo imaging. Here we show the design, synthesis and lysosome-responsive emission properties of a new NIR fluorophore. The NIR fluorescent probe design differs from typical amine functionalized lysosomotropic stains with off/on fluorescence switching controlled by a reversible phenol/phenolate interconversion. Emission from the probe is shown to be highly selective for the lysosomes in co-imaging experiments using a HeLa cell line expressing the lysosomal-associated membrane protein 1 fused to green fluorescent protein. The responsive probe is capable of real-time continuous imaging of fundamental cellular processes such as endocytosis, lysosomal trafficking and efflux in 3D and 4D. The advantage of the NIR emission allows for direct translation to in vivo tumour imaging, which is successfully demonstrated using an MDA-MB-231 subcutaneous tumour model. This bioresponsive NIR fluorophore offers significant potential for use in live cellular and in vivo imaging, for which currently there is a deficit of suitable molecular fluorescent tools.

13 July 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
BLBo Li
Bo Li
TCTriona Ni Chonghaile
Triona Ni Chonghaile
YFYue Fan
Yue Fan
SMStephen Madden
Stephen Madden
RKRut Klinger
Rut Klinger
WGWilliam M. Gallagher
William M. Gallagher
Triple-negative breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and effective targeted therapies for this disease. Here, we report evidence highlighting the cell-cycle–related kinase CDK7 as a driver and candidate therapeutic target in TNBC. Using publicly available transcriptomic data from a collated set of TNBC patients (n = 383) and the METABRIC TNBC dataset (n = 217), we found CDK7 mRNA levels to be correlated with patient prognosis. High CDK7 protein expression was associated with poor prognosis within the RATHER TNBC cohort (n = 109) and the METABRIC TNBC cohort (n = 203). The highly specific CDK7 kinase inhibitors, BS-181 and THZ1, each downregulated CDK7-mediated phosphorylation of RNA polymerase II, indicative of transcriptional inhibition, with THZ1 exhibiting 500-fold greater potency than BS-181. Mechanistic investigations revealed that the survival of MDA-MB-231 TNBC cells relied heavily on the BCL-2/BCL-XL signaling axes in cells. Accordingly, we found that combining the BCL-2/BCL-XL inhibitors ABT-263/ABT199 with the CDK7 inhibitor THZ1 synergized in producing growth inhibition and apoptosis of human TNBC cells. Collectively, our results highlight elevated CDK7 expression as a candidate biomarker of poor prognosis in TNBC, and they offer a preclinical proof of concept for combining CDK7 and BCL-2/BCL-XL inhibitors as a mechanism-based therapeutic strategy to improve TNBC treatment. Cancer Res; 77(14); 3834–45. ©2017 AACR.

28 February 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
SSSarah Shields
Sarah Shields
ECEmer Conroy
Emer Conroy
TOTony O'Grady
Tony O'Grady
AMAlo McGoldrick
Alo McGoldrick
KCKate Connor
Kate Connor
JCJudith A. Coppinger
Judith A. Coppinger
BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer

27 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Alice Claire O'FarrellAlice Claire O'Farrell
Alice Claire O'Farrell
RERhys Evans
Rhys Evans
JSJohanna M. U. Silvola
Johanna M. U. Silvola
IMIan Miller
Ian Miller
ECEmer Conroy
Emer Conroy
ABAnnette T Byrne
Annette T Byrne
Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism driven approaches for the early detection of cardiac dysfunction. We sought to interrogate changes in cardiac energy substrate usage during sunitinib treatment, hypothesising that these changes could represent a strategy for the early detection of cardiotoxicity. Balb/CJ mice or Sprague-Dawley rats were treated orally for 4 weeks with 40 or 20 mg/kg/day sunitinib. Cardiac positron emission tomography (PET) was implemented to investigate alterations in myocardial glucose and oxidative metabolism. Following treatment, blood pressure increased, and left ventricular ejection fraction decreased. Cardiac [18F]-fluorodeoxyglucose (FDG)-PET revealed increased glucose uptake after 48 hours. [11C]Acetate-PET showed decreased myocardial perfusion following treatment. Electron microscopy revealed significant lipid accumulation in the myocardium. Proteomic analyses indicated that oxidative metabolism, fatty acid β-oxidation and mitochondrial dysfunction were among the top myocardial signalling pathways perturbed. Sunitinib treatment results in an increased reliance on glycolysis, increased myocardial lipid deposition and perturbed mitochondrial function, indicative of a fundamental energy crisis resulting in compromised myocardial energy metabolism and function. Our findings suggest that a cardiac PET strategy may represent a rational approach to non-invasively monitor metabolic pathway remodeling following sunitinib treatment.

1 January 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DWDan Wu
Dan Wu
HDHarrison C Daly
Harrison C Daly
ECEmer Conroy
Emer Conroy
BLBo Li
Bo Li
WGWilliam M. Gallagher
William M. Gallagher
DODonal O'Shea
Donal O'Shea

14 October 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAdrian G. Murphy
Adrian G. Murphy
RCRory Casey
Rory Casey
AMAoife Maguire
Aoife Maguire
MTMiriam Tosetto
Miriam Tosetto
CBClare T. Butler
Clare T. Butler
Jacintha O' SullivanJacintha O' Sullivan
Jacintha O' Sullivan
Colorectal cancer (CRC) is a leading cause of cancer deaths. Molecularly targeted therapies (e.g. bevacizumab) have improved survival rates but drug resistance ultimately develops and newer therapies are required. We identified quininib as a small molecule drug with anti-angiogenic activity using in vitro, ex vivo and in vivo screening models. Quininib (2-[(E)-2-(Quinolin-2-yl) vinyl] phenol), is a small molecule drug (molecular weight 283.75 g/mol), which significantly inhibited blood vessel development in zebrafish embryos (p < 0.001). In vitro, quininib reduced endothelial tubule formation (p < 0.001), cell migration was unaffected by quininib and cell survival was reduced by quininib (p < 0.001). Using ex vivo human CRC explants, quininib significantly reduced the secretions of IL-6, IL-8, VEGF, ENA-78, GRO-α, TNF, IL-1β and MCP-1 ex vivo (all values p < 0.01). Quininib is well tolerated in mice when administered at 50 mg/kg intraperitoneally every 3 days and significantly reduced tumour growth of HT-29-luc2 CRC tumour xenografts compared to vehicle control. In addition, quininib reduced the signal from a αvβ3 integrin fluorescence probe in tumours 10 days after treatment initiation, indicative of angiogenic inhibition. Furthermore, quininib reduced the expression of angiogenic genes in xenografted tumours. Collectively, these findings support further development of quininib as a novel therapeutic agent for CRC.